How to Diagnose and Manage Patients With Fluoropyrimidine-Induced Chest Pain
Open Access
- 1 November 2020
- journal article
- editorial
- Published by Elsevier in JACC: Cardiooncology
- Vol. 2 (4) , 650-654
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- 5-FU induced cardiotoxicity: case series and review of the literatureCardio-Oncology, 2019
- Increased skeletal intermuscular fat is associated with reduced exercise capacity in cancer survivors: a cross-sectional studyCardio-Oncology, 2019
- Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or CapecitabineClinical Colorectal Cancer, 2019
- Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigmJournal of Gastrointestinal Oncology, 2017
- Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancerBMJ Open, 2016
- Effects of 5-Fluorouracil on Morphology, Cell Cycle, Proliferation, Apoptosis, Autophagy and ROS Production in Endothelial Cells and CardiomyocytesPLOS ONE, 2015
- A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicityBMC Pharmacology and Toxicology, 2014
- Fluorouracil Induces Myocardial Ischemia With Increases of Plasma Brain Natriuretic Peptide and Lactic Acid but Without Dysfunction of Left VentricleJournal of Clinical Oncology, 2010
- FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon CancerCancer Investigation, 2008
- Failure of Preventing 5-Fluorouracil Cardiotoxicity by Prophylactic Treatment with VerapamilActa Oncologica, 1990